Illumina, Inc.

ILMN · NASDAQ · USD

Can clinical sequencing demand keep growing fast enough to offset shrinking research budgets, cost inflation and pricing pressure from new competitors?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Clinical sequencing adoption

    The bull case is that clinical labs keep launching sequencing-intensive tests, so consumable demand grows faster than the underlying testing market.

  • NovaSeq X placement demand

    Instrument demand has stayed high well into the NovaSeq X cycle, and every placement adds a consumables stream that compounds as customers scale their testing.

  • Research funding recovery

    Research is the depressed part of the business, so any sustained recovery in grant spending would add revenue on top of the clinical growth already visible.

  • Operating margin expansion

    Cost programs already executed and a richer consumables mix are meant to carry operating margin toward the long-term target even before revenue accelerates.

Bear case

  • Research funding uncertainty

    The bear case is that academic and government funding stays unpredictable, so research consumables keep shrinking and eat into the clinical growth.

  • Competitor pricing per genome

    New sequencing entrants are competing on price per genome, which tests whether clinical customers will pay Illumina's pricing for workflow and data quality.

  • China export restrictions

    Illumina remains on China's restricted entity list, so instrument sales there stay limited and a slice of revenue is out of reach with no resolution date.

  • Cost inflation and tariffs

    Tariffs, memory component prices and freight are raising the cost of goods, forcing management to offset them with cuts rather than letting margin gains show through.

Bull and bear points

Growth & Execution

In short: Clinical consumables are growing fast, while research revenue keeps declining on funding uncertainty.

Bull · 2

  • Clinical consumables growth keeps running ahead of guidance

    Clinical testing is the largest growth driver, and management raised its full-year clinical outlook to mid-teens after two quarters of roughly 20% growth outside China, so the core revenue base is expanding faster than the company average.

    Q2 FY2026 call

  • New assays and data products add growth next year

    TruPath, spatial, proteomics and the Billion Cell Atlas are early, but management expects new products to contribute one to two points of growth in 2027, giving a second source of revenue beyond core sequencing.

    Q2 FY2026 call
Bear · 2

  • Research consumables keep declining as grant spending lags

    Management no longer describes research demand as stabilizing and guides research and applied consumables down mid to high single digits for 2026, so a profitable part of the base shrinks while clinical has to carry total growth.

    Tone shiftQ3 FY2025 → Q2 FY2026

  • Instrument growth slows against tougher second-half comparisons

    Placements are expected to stay elevated but year-over-year instrument growth moderates from here, and mid-throughput systems remain constrained by customer budgets, so the fastest-growing line is unlikely to repeat its first-half pace.

    Q2 FY2026 call

Profitability & Financial Strength

In short: Margins are expanding and cash flow is strong, while tariffs and component costs absorb part of the gain.

Bull · 1

  • Operating margin is still tracking toward the 2027 target

    Guidance implies roughly 350 basis points of margin expansion by the end of 2026 excluding acquisitions, and management still points to a 26% operating margin in 2027, so cost actions are converting into profit.

    Q1 FY2026 call
Bear · 2

  • Tariffs and memory costs keep gross margin from improving

    Gross margin of 66.4% rose less than revenue would suggest because tariffs, memory and freight costs consumed part of the gain, and management says the offsetting actions only become visible in the second half.

    Q2 FY2026 call

  • SomaLogic dilutes 2026 earnings and margin

    The acquisition adds revenue but is guided to cut operating margin by about 100 basis points and earnings per share by $0.18 this year, so reported profit growth understates the improvement in the underlying business.

    Q4 FY2025 call

Market Position

In short: Illumina holds the clinical installed base, but China restrictions and cheaper rival platforms pressure it.

Bull · 2

  • Largest clinical customers grow faster than the company

    Illumina's biggest clinical labs keep expanding sequencing capacity on its instruments and are projected to grow faster than the company average, which reinforces the installed base and the repeat consumables that follow it.

    Q3 FY2025 call

  • Whole genome and larger panels raise sequencing intensity

    Moves from exome to whole genome and larger oncology panels require several times more data per sample, so sequencing volume grows faster than test counts and lifts consumables revenue per customer.

    Q4 FY2025 call
Bear · 2

  • China restrictions stay unresolved and hold back instrument sales

    Illumina sits on China's unreliable entity list, its instrument sales there fell by more than half, and management guides the region flat with no timetable for resolution, so a former growth market stays largely closed.

    Q2 FY2026 call

  • Illumina has not set pricing for its next high-output flow cell

    Rivals are marketing lower prices per genome and management says it is not ready to discuss 35B flow cell pricing, so defending large clinical accounts may require conceding on price per gigabase.

    Q1 FY2026 call